Literature DB >> 24384090

Decorin blocks scarring and cystic cavitation in acute and induces scar dissolution in chronic spinal cord wounds.

Zubair Ahmed1, Daljeet Bansal2, Katie Tizzard2, Sarina Surey2, Maryam Esmaeili2, Ana Maria Gonzalez2, Martin Berry2, Ann Logan2.   

Abstract

In the injured central nervous system (CNS), transforming growth factor (TGF)-β1/2-induced scarring and wound cavitation impede axon regeneration implying that a combination of both scar suppression and axogenic treatments is required to achieve functional recovery. After treating acute and chronic dorsal funicular spinal cord lesions (DFL) in adult rats with the pan-TGF-β1/2 antagonist Decorin, we report that in: (1), acute DFL, the development of all injury parameters was significantly retarded e.g., wound cavity area by 68%, encapsulation of the wound by a glia limitans accessoria (GLA) by 65%, GLA basal lamina thickness by 94%, fibronectin, NG2 and Sema-3A deposition by 87%, 48% and 48%, respectively, and both macrophage and reactive microglia accumulations by 60%; and (2), chronic DFL, all the above parameters were attenuated to a lesser extent e.g., wound cavity area by 11%, GLA encapsulation by 25%, GLA basal lamina thickness by 31%, extracellular fibronectin, NG2 and Sema-3A deposition by 58%, 22% and 29%, respectively, and macrophage and reactive microglia accumulations by 44%. Moreover, in acute and chronic DFL, levels of tissue plasminogen activator (tPA) were raised (by 236% and 482%, respectively), as were active-MMP-2 (by 64% and 91%, respectively) and active-MMP-9 (by 122% and 18%, respectively), while plasminogen activator inhibitor-1 (PAI-1) was suppressed (by 56% and 23%, respectively) and active-TIMP-1 and active TIMP-2 were both lower but only significantly suppressed in acute DFL (by 56 and 21%, respectively). These findings demonstrate that both scar tissue mass and cavitation are attenuated in acute and chronic spinal cord wounds by Decorin treatment and suggest that the dominant effect of Decorin during acute scarring is anti-fibrogenic through suppression of inflammatory fibrosis by neutralisation of TGF-β1/2 whereas, in chronic lesions, Decorin-induction of tPA and MMP (concomitant with reduced complimentary levels of TIMP and PAI-1) leads to dissolution of the mature established scar by fibrolysis. Decorin also promoted the regeneration of similar numbers of axons through acute and chronic wounds. Accordingly, intrathecal delivery of Decorin offers a potential translatable treatment for scar tissue attenuation in patients with spinal cord injury.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Decorin; ECM; MMP; Scarring; Spinal cord injury; TIMP; tPA

Mesh:

Substances:

Year:  2013        PMID: 24384090     DOI: 10.1016/j.nbd.2013.12.008

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  20 in total

Review 1.  Matrix Metalloproteinases During Axonal Regeneration, a Multifactorial Role from Start to Finish.

Authors:  Lien Andries; Inge Van Hove; Lieve Moons; Lies De Groef
Journal:  Mol Neurobiol       Date:  2016-02-29       Impact factor: 5.590

2.  Attenuating the DNA damage response to double-strand breaks restores function in models of CNS neurodegeneration.

Authors:  Richard I Tuxworth; Matthew J Taylor; Ane Martin Anduaga; Alaa Hussien-Ali; Sotiroula Chatzimatthaiou; Joanne Longland; Adam M Thompson; Sharif Almutiri; Pavlos Alifragis; Charalambos P Kyriacou; Boris Kysela; Zubair Ahmed
Journal:  Brain Commun       Date:  2019-07-02

Review 3.  Molecular mechanisms of scar-sourced axon growth inhibitors.

Authors:  Yosuke Ohtake; Shuxin Li
Journal:  Brain Res       Date:  2014-09-01       Impact factor: 3.252

Review 4.  Recent advances in the pharmacologic treatment of spinal cord injury.

Authors:  April Cox; Abhay Varma; Naren Banik
Journal:  Metab Brain Dis       Date:  2014-05-16       Impact factor: 3.584

Review 5.  Serine Proteases and Chemokines in Neurotrauma: New Targets for Immune Modulating Therapeutics in Spinal Cord Injury.

Authors:  Roxana N Beladi; Kyle S Varkoly; Lauren Schutz; Liqiang Zhang; Jordan R Yaron; Qiuyun Guo; Michelle Burgin; Ian Hogue; Wesley Tierney; Wojciech Dobrowski; Alexandra R Lucas
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.708

Review 6.  Decorin treatment of spinal cord injury.

Authors:  Maryam Esmaeili; Martin Berry; Ann Logan; Zubair Ahmed
Journal:  Neural Regen Res       Date:  2014-09-15       Impact factor: 5.135

7.  Decorin treatment for reversing trabecular meshwork fibrosis in open-angle glaucoma.

Authors:  Lisa J Hill; Zubair Ahmed; Ann Logan
Journal:  Neural Regen Res       Date:  2016-06       Impact factor: 5.135

8.  Caveat emptor: for researchers, a rose will not smell sweet unless we know its composition.

Authors:  Josephine C Adams
Journal:  Biosci Rep       Date:  2017-05-11       Impact factor: 3.840

Review 9.  TGFβ-Directed Therapeutics: 2020.

Authors:  Beverly A Teicher
Journal:  Pharmacol Ther       Date:  2020-08-21       Impact factor: 12.310

10.  Decorin reduces hypertrophic scarring through inhibition of the TGF-β1/Smad signaling pathway in a rat osteomyelitis model.

Authors:  Peng Wang; Xiangyan Liu; Peng Xu; Jialiang Lu; Runze Wang; Weidong Mu
Journal:  Exp Ther Med       Date:  2016-08-12       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.